Cipla Q1 earnings beat forecast, leading to a rise in shares. The financial performance highlights growth in India.
Author: PharmaSignal News Desk
FDA waives trial requirement for Stelera biosimilar, marking a regulatory breakthrough and potentially reducing costs.
Bravehart Hengrui licensing involves a drug for hypertrophic cardiomyopathy, challenging Bristol Myers’ Camzyos in China.
Lilly has temporarily halted UK shipments of Mounjaro until Sept. 1, when new list prices take effect.
Treeline Biosciences, a biotech company founded by Loxo Oncology’s Josh Bilenker and former Novartis executive Jeff Engelman, has announced the advancement of three cancer drugs into Phase 1 clinical trials. This development is supported by a substantial $200 million……
Novartis licenses RNA medicine from Arrowhead in $200M deal
• Novartis signs billion-dollar biobuck deal with Argo in Shanghai. • Deal focuses on siRNA medicines development. • Novartis continues strategic investments in RNA-based therapies. Novartis signs a billion-dollar biobuck deal with Shanghai-based biotech company Argo, marking one of the largest agreements of its kind this year. The Swiss pharmaceutical giant is investing heavily in the development of small interfering RNA (siRNA) medicines, a promising area in the treatment of various diseases. This agreement follows a similar commitment made just a day earlier, highlighting Novartis’s strategic focus on RNA-based therapies. The financial terms of the deal include billions in potential…
Amgen to build $600m science and innovation centre in the US
European Parliament’s SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
Atlas Venture, one of the mainstay biotech venture capital firms, has collected its second batch of money within the past nine months.